Selank has been investigated using several administration methods, however, the majority of published studies have focused on intranasal administration. Researchers chose this route because peptides are easily degraded in the gastrointestinal tract, making oral administration less effective. Studies suggest that delivering Selank via the nasal cavity may allow for more efficient delivery of the peptide to the central nervous system, while bypassing degradation in the gastrointestinal tract [1,2].
For this reason, intranasal administration has become the primary method used in studies analysing Selank's effects on anxiety, stress resistance, cognitive functions, neuroprotection, gene expression, and the regulation of brain-derived neurotrophic factor (BDNF) [1-3].
Although some researchers and doctors have also analysed subcutaneous administration, there are significantly fewer publications available compared to intranasal use. The majority of human studies described in the scientific literature concern nasal administration, not injection protocols [1,4].
How is Selank Administered?
Scientific literature primarily describes Selank as a peptide administered nasally. This route of administration was chosen due to the low bioavailability of peptides after oral administration and their rapid breakdown in the gastrointestinal tract.
Research using intranasal Selank has examined, among other things, anxiety regulation, adaptation to stress, cognitive functions, neurotransmitter activity, BDNF expression, and interactions between the nervous and immune systems [1–4].
Nasal administration of Selank has also been shown to affect gene expression in brain structures such as the hippocampus, supporting its role as a neuroactive peptide delivered via the nasal mucosa [2].
How to Use Selank?
The precise method of administration depends on the formulation used and the research objective. Published studies have utilised standardised protocols developed to assess specific effects, such as anxiety reduction, cognitive enhancement, or neurobiological changes [1,4].
As Selank remains a research peptide in many countries, there are currently no widely accepted guidelines for its use approved by major regulatory bodies. Most available information stems from clinical trials, experimental research, and regional medical programmes, rather than official therapeutic recommendations.
For this reason, the procedures described in scientific studies should be treated as research methods, rather than general recommendations for use.
Selank reconstitution
What is a reconstitution?
Reconstitution is the process of dissolving lyophilised (freeze-dried) peptide powder in a sterile liquid prior to use.
Many peptides, including Selank, are supplied in freeze-dried form because in their dry powder state, they retain greater stability. Before use in research, the peptide is mixed with an appropriate sterile solvent to create a solution intended for a specific route of administration.
How to Reconstitute Selank?
From a laboratory perspective, reconstitution involves carefully adding a sterile diluent to a vial containing lyophilised peptide and allowing it to dissolve completely.
However, published literature concerning Selank does not contain standardised reconstitution procedures, dilution proportions, or universally accepted preparation methods. As a result, there is no single evidence-based protocol applicable to all Selank-containing products [1–4].
The method of preparation may vary depending on the vial size, peptide concentration, formulation requirements, and intended route of administration. Researchers typically follow the instructions provided by the manufacturer of the product being studied.
How to reconstitute 5mg or 10mg of Selank?
Scientific literature does not contain validated instructions for the reconstitution of vials containing 5 mg or 10 mg of Selank.
Although various dilution methods are often discussed online, they are typically based on laboratory practices rather than published clinical evidence. As solvent volume directly affects concentration, stability, and dosing accuracy, researchers usually follow the manufacturer's instructions for a specific preparation.
Without detailed guidelines for a given formulation, there is no single scientifically proven answer specifying the amount of solvent needed to prepare a 5 mg or 10 mg vial.
How much bacteriostatic water for 10mg of Selank?
Current studies do not specify a standard volume of bacteriostatic water for a vial containing 10 mg of Selank.
The amount of solvent used determines the final concentration of the solution, and different research protocols may require different concentrations. As there is no universally accepted concentration in the literature, the appropriate volume depends on the specific formulation.
How to Prepare a Nasal Spray with Selank?
Research confirms the possibility of intranasal administration of Selank, however, it does not contain validated instructions for the preparation or compounding of nasal spray formulations [2,3].
Developing a stable peptide spray requires significantly more than dissolving a powder in water. Professional formulations consider, among other factors, sterility, appropriate pH, osmolality, stability, the presence of preservatives, and the peptide's degradation rate.
As these factors directly affect the quality and durability of the product, the scientific literature does not present a simple, evidence-based method for preparing a homemade Selank spray.
How to Mix Selank for Nasal Spray
Available research shows that Selank retains biological activity after intranasal administration, however, published works do not describe standardised procedures for preparing nasal spray formulations [2,3].
Consequently, there currently isn't a universally accepted scientific protocol defining the exact amount of solvent, spray concentration, buffer composition, preservative system, or shelf-life for a preparation containing Selank.
These parameters are usually determined during the pharmaceutical product development and formulation research process, rather than during clinical efficacy studies.
How to reconstitute Selank for nasal spray?
The majority of research into intranasal Selank focuses on biological effects, such as anxiety reduction, neuroprotection, BDNF regulation, antiviral activity, or effects on neurotransmitters, rather than formulation chemistry [1–4].
Therefore, although current data indicate that nasal administration is the best-researched route of administration, the literature does not specify a single validated method for transforming Selank powder into a ready-to-use nasal spray.
Summary
Current research indicates that intranasal administration is the most well-researched method of using Selank. The majority of published studies analysing its effect on anxiety, stress resilience, cognitive functions, neuroprotection, and the regulation of neurobiological processes have utilised this route of administration.
Despite the increasing number of studies on the biological effects of Selank, there are currently no widely accepted standards for its administration, reconstitution, or the preparation of nasal sprays. Further pharmaceutical and clinical research will be necessary to develop standardised procedures and formulation guidelines.
Disclaimer
This material is for educational and informational purposes only. Selank remains a research peptide in many jurisdictions, and universally accepted standards for its administration, compounding, or reconstitution have not been established in the published scientific literature.
For research purposes only: Selank products available from Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption, medical use, diagnosis, treatment or the prevention of disease. All research materials should be handled by qualified personnel in accordance with applicable regulations and the principles of good laboratory practice.
References
[1] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[2] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[3] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[4] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642